FNCHQ (Finch Therapeutics Group) Institutional Ownership: 1.32% (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Institutional Ownership?

Finch Therapeutics Group FNCHQ 12 Institutional Ownership is 1.32% as of Aug. 19, 2026. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Finch Therapeutics Group's institutional ownership is 1.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Finch Therapeutics Group's Insider Ownership is 6.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Finch Therapeutics Group's Float Percentage Of Total Shares Outstanding is 43.17%.

Finch Therapeutics Group Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Institutional Ownership Chart

Finch Therapeutics Group Historical Data

The historical data trend for Finch Therapeutics Group can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.32% mean?
Finch Therapeutics Group (FNCHQ) has a Institutional Ownership of 1.32% as of Aug. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Institutional Ownership too high?
Finch Therapeutics Group's current Institutional Ownership is 1.32%. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Institutional Ownership compare to CRIS and LSB?
Finch Therapeutics Group's Institutional Ownership of 1.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Institutional Ownership is 1.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Institutional Ownership of 1.32%. The current Institutional Ownership is 1.32%. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Institutional Ownership is 1.32% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price